TRANSLATE-TIMI 70

TRANSLATE-TIMI 70 is a phase 2b trial testing multiple doses of vupanorsen, an antisense oligonucleotide (ASO) against angiopoietin-like 3 (ANGPTL3) mRNA, for safety and efficacy in non-HDL-C lowering.

TRANSLATE Schema

MAIN RESULTS:
Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70
Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol_ TRANSLATE-TIMI 70

Circulation. 2022 May 3;145(18):1377-1386.

PRESENTATIONS

TRANSLATE Main Results (Bergmark ACC 2022)
Hepatic Fat Changes After An Antisense Oligonucleotide Therapy Targeting ANGPTL3: A TRANSLATE-TIMI 70 Analysis (Zimerman, ACC 2023)

TRANSLATE on ClinicalTrials.gov

CONTACT US about TRANSLATE

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close